Acrivon Therapeutics (ACRV) Cash & Current Investments (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Cash & Current Investments for 6 consecutive years, with $97.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 34.68% year-over-year to $97.7 million; the TTM figure through Mar 2026 stood at $97.7 million (down 34.68% YoY), while the FY2025 annual figure was $118.6 million, down 33.93% from the prior year.
• Cash & Current Investments fell to $97.7 million in Q1 2026 per ACRV's latest filing, from $118.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $187.5 million in Q3 2024 and bottomed at $76.8 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $130.0 million across 5 years, with a median of $127.8 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments soared 2025.71% — and 2026, when it tumbled 34.68%.
• Acrivon Therapeutics' Cash & Current Investments stood at $127.8 million in 2022, then dropped by 0.23% to $127.5 million in 2023, then jumped by 40.82% to $179.5 million in 2024, then tumbled by 33.93% to $118.6 million in 2025, then fell by 17.58% to $97.7 million in 2026.
• Business Quant data shows ACRV's Cash & Current Investments at $97.7 million in Q1 2026, $118.6 million in Q4 2025, and $129.3 million in Q3 2025.